The IRA is here to stay. How can brand and access leaders adapt?

The IRA (Inflation Reduction Act) is much more than a passing threat. As key provisions are proceeding, it is looking less likely that the IRA will be challenged in congress. Manufacturers may need to consider multiple different adjustments to bolster branded patient support programming.

As the industry grapples with the realities of price negotiations, inflation penalties, and Part D redesign, manufacturers must adapt their hub and copay programs to ensure continued patient access and affordability.

The IRA may have rewritten the rulebook, but with strategic adaptations and a patient-centric focus, manufacturers can continue to deliver effective patient support programs that meet the evolving needs of patients in this new era of drug pricing.

Join ConnectiveRx for an in-depth look at how brand and access leaders can continue to offer robust patient support despite the challenges brought about by the IRA.

Register for live and on-demand access!

Featuring a conversation with:

Dowd - Chris 2023 (2)
SVP, Market Development, ConnectiveRx
Bill Sarraille circle picture
Adjunct Professor, University of Maryland, Francis King Cary School of Law
Joel White 2-1
President, Council for Affordable Health Coverage